Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

Exclusion Criteria

• •Diagnosis of Alzheimer's disease according to the (DSM-IV-TR) or NINCDS-ADRDA criteria.
• •Any medical condition that could explain the patients cognitive deficits.
• •CT or MRI brain imaging results obtained within 12 months prior to baseline showing evidence of infection, infarction, or focal lesions of clinical significance
• •MRI scan at screening showing more than 4 cerebral microhemorrhages (lesions with diameter ≤ 10 mm).
• •Geriatric Depression Scale (30-point scale) score \> 9 at screening.
• •History of stroke.
• •Modified Hachinski ischemic scale score \> 4 at screening.
• •Women of childbearing potential.
• •Vitamin B12 or folate deficiency.
• •Diagnosis of schizophrenia or recurrent mood disorder (including unipolar and bipolar disorders) within 3 years of screening.
• •Current diagnosis of peptic ulcer or gastrointestinal bleeding within the last year and/or chronic inflammatory bowel disease.
• •Concomitant use of donepezil at doses \> 5 mg/day or other cholinesterase inhibitors (rivastigmine or galantamine) at any dose.
• •Concomitant use of memantine at dose \> 20 mg/day.
• •Concomitant use of psychoactive drugs (sedatives, hypnotics, etc).